Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-040008
Filing Date
2025-08-13
Accepted
2025-08-13 08:03:46
Documents
71
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20250630.htm   iXBRL 10-Q 1350809
2 EX-31.1 ovid2025q2exhibit311.htm EX-31.1 10557
3 EX-31.2 ovid2025q2exhibit312.htm EX-31.2 10576
4 EX-32.1 ovid2025q2exhibit321.htm EX-32.1 5933
10 ovid-20250630_g1.jpg GRAPHIC 128841
  Complete submission text file 0001628280-25-040008.txt   7272721

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20250630.xsd EX-101.SCH 50788
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ovid-20250630_cal.xml EX-101.CAL 64310
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20250630_def.xml EX-101.DEF 218195
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20250630_lab.xml EX-101.LAB 643627
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20250630_pre.xml EX-101.PRE 436155
74 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20250630_htm.xml XML 863157
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 251209053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)